Sabine Helfen

Statistics

Publications

Citations

H-Index

Active since

2018

Affiliations

Hôpital Bichat-Claude-Bernard(Current)

Université de Bordeaux

Assistance Publique – Hôpitaux de Paris

Université Grenoble Alpes

Centre Hospitalier Universitaire de Bordeaux

Sabine Helfen is an author at Hôpital Bichat-Claude-Bernard specializing in recist criteria, tumor response evaluation, and checkpoint inhibitor therapy.

Publications per year

2018–2019

Publications

Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: Interim results of the phase 2 CARSKIN trial.

E. Maubec, Marouane Boubaya, Peter Petrow et al. · Journal of Clinical Oncology · 2018 · 24 citations

Medicine, Oncology, Pharmacology +17

Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN.

E. Maubec, Marouane Boubaya, Peter Petrow et al. · Journal of Clinical Oncology · 2019 · 19 citations

Medicine, Oncology, Pharmacotherapy +17

1–2 of 2